Redeye has lowered organic growth expectations for Stillfront following a weaker than expected outlook for 2022. However, as we have also added the acquisitions of Jawaker and 6Waves to our estimates our overall revenue and EBITDA estimates are up 8-11% for 2022-23E.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases